Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060489 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00060489 is a Phase 3 study that has completed, run by AstraZeneca.
The verdict
NCT00060489, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
Interventions
- DRUG SEROQUEL (quetiapine fumarate) Tablets
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060489
The ClinicalTrials.gov registry entry for NCT00060489 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SEROQUEL (quetiapine fumarate) Tablets is the first listed.
NCT00060489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060489 about?
NCT00060489 is a clinical study titled "Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression". The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
What is the current status of trial NCT00060489?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-09. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00060489?
The interventions under investigation include: SEROQUEL (quetiapine fumarate) Tablets (DRUG).
Who is sponsoring clinical trial NCT00060489?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.